INNOGEN-B (02591) announced that despite generating revenue of approximately RMB 131.5 million in 2025 (2024: zero) following the commercial launch of its core product, Eisupaglutide α, for the treatment of type 2 diabetes in China and Macau, the Group expects to record a loss of approximately RMB 341.4 million for the current year. This compares to a loss of approximately RMB 174.7 million for the year ended December 31, 2024.

The increase in loss for the current year is primarily attributed to (i) an increase in research and development expenses of approximately RMB 103.3 million, mainly due to higher costs for raw materials, preclinical studies, clinical trials, and process optimization related to the lifecycle management and clinical development of Eisupaglutide α. This includes Phase IIb/III clinical trials in China for treating obesity and overweight, and a Phase II clinical study in Australia; and (ii) an increase in sales and distribution expenses of approximately RMB 174.3 million, largely driven by higher marketing and promotion costs following the commercial launch of Eisupaglutide α, as well as increased employee benefits expenses resulting from the expansion of the sales team to support market development.